8-K - VASO - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report: March 25, 2020

(Date of earliest event reported)

VASO CORPORATION

(Exact name of registrant as specified in charter)

Delaware	0-18105	11-2871434
(State<br>or other jurisdiction	(Commission<br>File	(IRS<br>Employer
of<br>incorporation)	Number)	Identification<br>No.)
137<br>Commercial Street, Suite 200, Plainview, New York	11803
---	---
(Address<br>of principal executive offices)	(Zip<br>Code)

Registrant’s telephone number, including area code: (516) 997-4600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□	Written<br>communications pursuant to Rule 425 under the Securities Act (17<br>CFR 230.425)
□	Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR<br>240.14a-12)
□	Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17<br>CFR 240.14d-2(b))
□	Pre-commencement<br>to communications pursuant to Rule 13e-4(c) under the Exchange Act<br>(17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title<br>of each class	Trading<br>Symbol(s)	Name of<br>each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountant standards provided pursuant to Section 13(a) of the Exchange Act. □

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On March 25, 2020, Jane Moen (40 years of age) was appointed by the Board of Directors as a Class II director of the Company for which she will be receiving 1,000,000 shares of restricted common stock vesting over a four-year period. As an accomplished sales professional, Ms. Moen has been President of the Company’s wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare since June 2018 following a remarkable career track record at VasoHealthcare, starting as an Account Manager at the inception of VasoHealthcare in April 2010 and being promoted to Regional Manager in January 2012, Director of Product Business Lines in July 2012 and Vice President of Sales in April 2016. Jane Moen has been in the medical sales industry for over 17 years, having had prior experience with Ledford Medical Sales, Vital Signs, Inc., Pfizer Inc. and Ecolab, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VASO CORPORATION
Date:<br>March 31, 2020	By:	/s/ Jun<br>Ma
		Jun<br>Ma
		Chief<br>Executive Officer and President